VERAXA Biotech Starts Cell Line Development for Lead BiTAC Therapy, Shares Jump 18.3%
VRXA•VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager cancer therapy program, a critical preclinical step for manufacturing and characterization. Shares jumped 18.3% on July 2, reflecting investor enthusiasm as the company readies the program for IND-enabling studies.
1. Initiation of Cell Line Development
VERAXA has begun generating stable cell lines to produce its lead BiTAC T-cell engager candidate, marking a key step toward scalable protein production. This process establishes the foundation for in vitro potency and manufacturability assessments essential for advancing toward IND-enabling studies.
2. BiTAC Platform Context
The BiTAC platform utilizes bi-specific molecules that direct patient T cells to tumor antigens, enhancing targeted cytotoxicity. The lead program leverages proprietary linker technology to optimize binding affinity and stability, positioning it as a potential best-in-class candidate in the TCE market.
3. Market Reaction and Next Steps
Following the announcement, shares rose 18.3%, signaling positive market response to the development milestone. VERAXA plans to complete cell line optimization and scale-up by Q4 2026, followed by toxicology studies and regulatory filings in early 2027.
